Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects

The past decade has witnessed great advances in the treatment of chronic myeloid leukemia (CML), brought about in large part by the development of BCR-ABL tyrosine kinase inhibitors (TKIs). Bosutinib joins the armamentarium of approved TKIs for the treatment of chronic phase (CP), accelerated phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Ault, Patricia S., Rose, PharmD, John, Nodzon, PhD, Lisa A., Kaled, Elizabeth S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226309/
https://www.ncbi.nlm.nih.gov/pubmed/28090366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226309/
https://www.ncbi.nlm.nih.gov/pubmed/28090366

Ejemplares similares